Program:
3/10-Registration-KEYNOTE ADDRESS: F. Lejeune , CHUV, "The Mechanism of Anti-Tumor
Activity of High Dose Intravascular TNF"Mon. 3/11-MECHANISMS OF ANTITUMOR
EFFECT WITH TNF I: N. Jaskowiak, National Cancer Inst, "Secondary Cytokine Production
and Endocrine Effects after High Dose Intravascular TNF"; H. Dvorak, Beth Israel Hosp,
"Pathology of Responding Tumors Following Isolation Perfusion with TNF"; Speakers to be
Announced-POSTER SESSION 1-MECHANISMS OF ANTITUMOR EFFECT WITH TNF II:
M. Schwarz, Columbia Univ, "EMAPII: A Novel Antiangiogenic Cytokine"; R. Jain ,
Massachusetts General Hosp, "Tumor Interstitial Hydrostatic Pressure: Effects of TNF and
Impact on Delivery of Intravascular Agents"; P. Nooijen , Univ Hospital-Nijmegan, "Effect of
High Dose TNF Delivered by Regional Perfusion on Vascular Endothelial Cells"Tues. 3/12-
SYNERGISTIC ACTION BETWEEN TNF, CHEMOTHERAPEUTICS, AND
HYPERTHERMIA I: I. Robins, Univ Wisconsin Cancer Ctr, "The Use of Systemic TNF in
Conjunction with Whole Body Hyperthermia and Chemotherapeutics"; J. Klostergaard, MD
Anderson Cancer Ctr, "Preclinical Studies of Modified and Liposomal TNF"; B. Bonavida , Univ
California-Los Angeles, "Synergistic Cytotoxic Interactions of TNF with Chemotherapeutics";
Speaker to be Announced-POSTER SESSION 2-SYNERGISTIC ACTION BETWEEN TNF,
CHEMOTHERAPEUTICS, AND HYPERTHERMIA II: Speakers to be AnnouncedWed. 3/13-
DIRECT CYTOTOXICITY WITH TNF AND RECEPTOR SELECTIVE MUTEINS I: W.
Fiers, Univ Ghent, "TNF-Receptor Specific TNF Mutants: Mechanism of Action at the Cellular
and in vivo Level"; J. Fruehauf, Oncotech, Inc, "A GKD TNF Degradation Products Contributes
to TNF Antitumor Activity: Preclinical Development and Characterization"; D. Spriggs , Sloan-
Kettering Cancer Center, "Production of TNF as a Mechanism for Proposed Resistence to TNF
Cytotoxicity in vitro"-POSTER SESSION 3-DIRECT CYTOTOXICITY WITH TNF AND
RECEPTOR SELECTIVE MUTEINS I: C. Ware , Univ California-Riverside, "Characterization
and Signaling Through Distinct TNF Receptors"; S. Jacobsen, Hipple Cancer Rsch Ctr, "The
Role of TNF and Fas in Hematopoiesis"; Speaker to be AnnouncedThur. 3/14-POTENTIAL
CLINICAL USE OF RELATED CYTOKINES I: G. Wong, Genentech, Inc, "New Clinical
Indications for Lymphotoxin"; D. Vlock , Brigham and Women's Hosp, "Potential Clinical
Applications of Recombinant IL-1"; C. Johnson, Univ Pittsburgh Sch Med, "Cytokine
Enhancement of Chemotherapeutic Efficacy: Role of the Vasculature"-POSTER SESSION 4-
POTENTIAL CLINICAL USE OF RELATED CYTOKINES II: Speakers to be AnnouncedFri.
3/15-CLINICAL TRIALS OF REGIONAL TNF I: A. Eggermont, Rotterdam Cancer Inst,
"Limb Perfusion with TNF: Current Status of European Trials"; J. Klausner, Tel Aviv Univ,
"The Use of TNF in Isolated Limb Perfusion for Treatment of Unresectable Extremity Sarcoma";
D. Fraker, National Cancer Inst, "Isolated Hepatic Perfusion with TNF"; D. Fraker, Univ
Pennsylvania, "Limb Perfusion with TNF: Current Status of United States Trials"-CLINICAL
TRIALS OF REGIONAL TNF II: H. Pass , National Cancer Inst, "Isolated Lung Perfusion with
TNF"; R. Alexander, National Cancer Inst, "The Use of TNF in Continuous Hyperthermic
Peritoneal Perfusions"; D. Lienard , CHUV, "The Use of TNF in Isolated Limb Perfusion for
Treatment of Locally Advanced Melanoma"-Banquet (Please note: There are NO POSTERS on
banquet day.)Sat. 3/16-Departure
Registration :
For more Information: Cambridge Symposia
1037 Chestnut Street
Newton Upper Falls, MA 02164
USA
Phone:617-630-1399
Fax: 617-630-1395
Deadline for Abstracts: December 6, 1995
Email for Requests and Registration: symposia@xensei.com